Skip to main content
      Sjögren's disease has been a difficult space for new FDA approvals. At ACR 2025, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
      What Can we do About Chronic Pain?
      Prof. Sandra Navarra and colleagues compared the efficacy and safety of tacrolimus and glucocorticoids vs. mycophenolate mofetil (MMF) as a continuous induction-maintenance treatment for class III/IV+V lupus nephritis.
      Late-Breaking Trials in axSpA and PsA
      Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
      Rheumatology Roundup
      New Gout Therapies Show Promise in Phase III Trials

      At #ACR25, the American College of Rheumatology’s annual meeting

      Dr. John Cush RheumNow

      2 days 13 hours ago
      New Gout Therapies Show Promise in Phase III Trials At #ACR25, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices https://t.co/Ff16L2CHc0
      #ACR25 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases At #ACR25, ne

      Dr. John Cush RheumNow

      3 days 3 hours ago

      #ACR25 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases At #ACR25, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. https://t.co/CPob0ppjv3

      Upadacitinib is a Double Edged Vascular Sword in GCA

      Dr. David Liew discusses abstracts O751, O738, and O734 presented

      Dr. John Cush RheumNow

      3 days 7 hours ago
      Upadacitinib is a Double Edged Vascular Sword in GCA Dr. David Liew discusses abstracts O751, O738, and O734 presented at #ACR25. https://t.co/eTmVehP2Cd https://t.co/vxehwRWM2D
      Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty.  Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!
      Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our articles, videos and podcasts.
      Every year I love the late breaking abstracts. It’s consistently my favourite part of the meeting program, by some distance. Here's why you should love them, too.
      ×